Omkar Speciality Chemicals Schedules Board Meeting to Review Financials Amid Ongoing CIRP
Omkar Speciality Chemicals Limited has scheduled a Board of Directors meeting for Friday, August 07, 2026, to address and approve several key financial statements. The meeting is set to review both audited and unaudited results spanning multiple financial years.The agenda requires the company to consider and approve three specific sets of financial statements:
- Unaudited Financial Statements for all quarters and Audited Financial Statements for the year ended March 31, 2025.
- Unaudited Financial Statements for all quarters and Audited Financial Statements for the year ended March 31, 2024.
- Unaudited Financial Statements of the Company for September-2022 and December 2022, along with Audited Financial Statements for the year ended on March 31, 2023.
The company provided context regarding the delays in submitting these financial results. Omkar Speciality Chemicals has been operating under a Corporate Insolvency Resolution Process (CIRP) as per the Insolvency and Bankruptcy Code, 2016. The delay in completing the quarterly, half-yearly, and yearly financial results from the financial years spanning 2022 to 2025 is attributed to circumstances prevailing during the CIRP period. These operational challenges specifically include the resignation of Key Managerial Personnel (KMP), non-availability of necessary records, and general operational constraints.
Due to the ongoing suspension of trading in the equity shares of the company on both the Bombay Stock Exchange and the National Stock Exchange of India Limited, a separate announcement regarding the closure of the Trading Window connected with the Board Meeting has not been made, as the securities are currently unavailable for trading on the exchanges.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.